Revolution Medicines, Inc. (FRA:42Z)
Germany · Delayed Price · Currency is EUR 67.00
-2.00 (-2.90%)
At close: Nov 28, 2025
Revolution Medicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| - | - | 11.58 | 35.38 | 29.39 | 42.98 | Upgrade | |
Revenue Growth (YoY) | - | - | -67.27% | 20.38% | -31.62% | -14.10% | Upgrade |
Cost of Revenue | 880.49 | 592.23 | 411.24 | 253.07 | 186.95 | 132.25 | Upgrade |
Gross Profit | -880.49 | -592.23 | -399.66 | -217.69 | -157.56 | -89.27 | Upgrade |
Selling, General & Admin | 156.57 | 97.3 | 62.02 | 40.59 | 30.45 | 21.43 | Upgrade |
Operating Expenses | 156.57 | 97.3 | 62.02 | 40.59 | 30.45 | 21.43 | Upgrade |
Operating Income | -1,037 | -689.52 | -461.69 | -258.28 | -188.01 | -110.7 | Upgrade |
Interest Expense | -12.3 | - | -0.3 | - | -0.01 | -0.07 | Upgrade |
Interest & Investment Income | 90.63 | 86.88 | 47.48 | 9.15 | 0.93 | 2.24 | Upgrade |
Other Non Operating Income (Expenses) | -3.01 | 1.8 | 0.12 | - | - | - | Upgrade |
EBT Excluding Unusual Items | -961.73 | -600.85 | -414.39 | -249.13 | -187.09 | -108.53 | Upgrade |
Merger & Restructuring Charges | - | - | -25.5 | - | - | - | Upgrade |
Pretax Income | -961.73 | -600.85 | -439.89 | -249.13 | -187.09 | -108.53 | Upgrade |
Income Tax Expense | -0.75 | -0.75 | -3.52 | -0.42 | - | -0.37 | Upgrade |
Net Income | -960.98 | -600.09 | -436.37 | -248.71 | -187.09 | -108.16 | Upgrade |
Preferred Dividends & Other Adjustments | - | - | - | - | - | 2.22 | Upgrade |
Net Income to Common | -960.98 | -600.09 | -436.37 | -248.71 | -187.09 | -110.38 | Upgrade |
Shares Outstanding (Basic) | 185 | 168 | 113 | 81 | 73 | 55 | Upgrade |
Shares Outstanding (Diluted) | 185 | 168 | 113 | 81 | 73 | 55 | Upgrade |
Shares Change (YoY) | 15.98% | 48.24% | 40.34% | 10.74% | 32.68% | 1879.16% | Upgrade |
EPS (Basic) | -5.19 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | Upgrade |
EPS (Diluted) | -5.19 | -3.58 | -3.86 | -3.08 | -2.57 | -2.01 | Upgrade |
Free Cash Flow | -777.08 | -567.74 | -358.3 | -235.22 | -153.71 | -103 | Upgrade |
Free Cash Flow Per Share | -4.20 | -3.38 | -3.17 | -2.92 | -2.11 | -1.88 | Upgrade |
Gross Margin | - | - | - | - | - | -207.68% | Upgrade |
Operating Margin | - | - | -3986.92% | -730.01% | -639.70% | -257.54% | Upgrade |
Profit Margin | - | - | -3768.28% | -702.95% | -636.58% | -256.80% | Upgrade |
Free Cash Flow Margin | - | - | -3094.14% | -664.83% | -522.99% | -239.62% | Upgrade |
EBITDA | -1,030 | -683 | -456.68 | -254.34 | -184.96 | -108.12 | Upgrade |
EBITDA Margin | - | - | - | - | - | -251.54% | Upgrade |
D&A For EBITDA | 7.22 | 6.53 | 5.01 | 3.94 | 3.05 | 2.58 | Upgrade |
EBIT | -1,037 | -689.52 | -461.69 | -258.28 | -188.01 | -110.7 | Upgrade |
EBIT Margin | - | - | - | - | - | -257.54% | Upgrade |
Revenue as Reported | - | - | 11.58 | 35.38 | 29.39 | 42.98 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.